Health Boards
This study published in The British Journal of Dermatology suggests clinicians should avoid intermittent treatment with Infliximab (Remicade) for psoriasis.
Background:
Continuous maintenance therapy with infliximab 5 mg/kg every 8 weeks is effective for moderate-to-severe plaque-type psoriasis.
Objective:
This study evaluated efficacy and safety of continuous versus intermittent infliximab maintenance therapy.
Methods:
RESTORE2 was a long-term extension of RESTORE1. At baseline of RESTORE2, eligible patients who had received infliximab for 26 weeks and achieved Psoriasis Area and Severity Index (PASI) 75 in RESTORE1 were re-randomised 1:1 to continuous therapy (infliximab 5 mg/kg every 8 weeks) or intermittent therapy (no infliximab until >50% loss of PASI improvement). Safety and efficacy assessments occurred throughout the study.
Results:
222 patients were randomised to receive continuous therapy; 219 to intermittent therapy. Numerically more serious infusion-related reactions occurred with intermittent therapy (8/219 patients, 4%) than continuous therapy (1/222 patients, <1%), leading the sponsor to terminate the study. Mean duration of exposure to infliximab was 40.12 weeks (SD = 27.55,) with a mean of 5.8 infusions (range, 0–16) for continuous therapy and 22.78 weeks (SD = 22.98) with a mean of 3.4 infusions (range, 0–16) for intermittent therapy. Although no formal efficacy analyses were conducted, continuous therapy led to numerically greater PASI 75 at week 52 in the continuous group (81/101, 80%) than in the intermittent group (39/83, 47%); several other efficacy measures demonstrated similar patterns.
Conclusions:
For patients with moderate-to-severe plaque-type psoriasis, continuous therapy with infliximab may be more effective than intermittent therapy. The incidence of serious infusion-related reactions in the intermittent group suggests that clinicians should avoid intermittent therapy in this population.
Source: NO LINKS ALLOWED
Background:
Continuous maintenance therapy with infliximab 5 mg/kg every 8 weeks is effective for moderate-to-severe plaque-type psoriasis.
Objective:
This study evaluated efficacy and safety of continuous versus intermittent infliximab maintenance therapy.
Methods:
RESTORE2 was a long-term extension of RESTORE1. At baseline of RESTORE2, eligible patients who had received infliximab for 26 weeks and achieved Psoriasis Area and Severity Index (PASI) 75 in RESTORE1 were re-randomised 1:1 to continuous therapy (infliximab 5 mg/kg every 8 weeks) or intermittent therapy (no infliximab until >50% loss of PASI improvement). Safety and efficacy assessments occurred throughout the study.
Results:
222 patients were randomised to receive continuous therapy; 219 to intermittent therapy. Numerically more serious infusion-related reactions occurred with intermittent therapy (8/219 patients, 4%) than continuous therapy (1/222 patients, <1%), leading the sponsor to terminate the study. Mean duration of exposure to infliximab was 40.12 weeks (SD = 27.55,) with a mean of 5.8 infusions (range, 0–16) for continuous therapy and 22.78 weeks (SD = 22.98) with a mean of 3.4 infusions (range, 0–16) for intermittent therapy. Although no formal efficacy analyses were conducted, continuous therapy led to numerically greater PASI 75 at week 52 in the continuous group (81/101, 80%) than in the intermittent group (39/83, 47%); several other efficacy measures demonstrated similar patterns.
Conclusions:
For patients with moderate-to-severe plaque-type psoriasis, continuous therapy with infliximab may be more effective than intermittent therapy. The incidence of serious infusion-related reactions in the intermittent group suggests that clinicians should avoid intermittent therapy in this population.
Source: NO LINKS ALLOWED